Ginkgo Flavone Glycosides

Compound Class	Flavonol glycosides — quercetin, kaempferol, and isorhamnetin conjugated to glucose, rhamnose, or glucorhamnose
Representative Members	Quercetin glycosides, kaempferol glycosides, isorhamnetin glycosides; plus Ginkgo-specific acylated flavonol glycosides
Botanical Sources	Ginkgo biloba (maidenhair tree)
Plant Part(s)	Leaf
Typical Standardisation	24% flavone glycosides — the first half of the classic 24%/6% EGb 761 specification. Ginkgolic acids must be <5 ppm
Primary Applications	Cognitive and cerebrovascular formulation; antioxidant positioning; typically co-specified with terpene lactones
Claim Strength (Overview)	Emerging — large trials show no dementia-prevention benefit; symptomatic benefit in existing cognitive impairment is dose-dependent and contested
Buy from Herbuno	Ginkgo Biloba Extract 24%/6% Powder (Ginkgo) | Standardized Ginkgo biloba → Ginkgo Biloba Extract Powder →

Name origin: The flavone (more precisely flavonol) glycosides of ginkgo are named descriptively rather than after the plant: the aglycones are quercetin, kaempferol, and isorhamnetin — ubiquitous plant flavonols — conjugated to sugar units. What is distinctive to Ginkgo biloba is not the aglycones themselves but a set of Ginkgo-specific acylated flavonol glycosides, which appear to contribute activity that ordinary flavonols do not. Traditional use: Ginkgo biloba is a living fossil with no close living relatives, and its traditional use is largely a story about the seed rather than the leaf: ginkgo nuts appear in Chinese materia medica for respiratory complaints and are eaten as food. The leaf extract that dominates the global supplement market is essentially a 20th-century European pharmaceutical development, not an inherited traditional preparation — a distinction worth stating plainly rather than allowing "ancient tree" marketing to imply otherwise. Research trajectory: The defining event in this field was the standardization of EGb 761 — an acetone-extracted leaf preparation adjusted to 24% flavone glycosides and 6% terpene lactones, with ginkgolic acids held below 5 ppm. This became the reference material for a large clinical literature. The equally defining event was the Ginkgo Evaluation of Memory (GEM) study, the largest dementia-prevention trial ever conducted on the extract, which returned a null result. Commercial source: Ginkgo biloba leaf extract standardized to the 24%/6% ratio is the industry-standard commercial format; note that flavone glycosides and terpene lactones are two chemically distinct fractions co-specified in a single extract.

---

Evidence for Ginkgo Flavone Glycosides Applications

The standardization convention itself is the foundational fact and deserves precise statement: EGb 761 is produced from ginkgo leaves and contains 24% flavone glycosides and 6% terpene lactones, with the active constituents comprising flavonoids and terpenoids — the terpene lactones (ginkgolides and bilobalide) being unique to Ginkgo biloba. Standardized extracts were formulated precisely because of concerns about huge variability in the composition of unstandardized preparations, with season and growing environment affecting content in ways that carry implications for both efficacy and safety (Cochrane Review). The 24% figure on a certificate of analysis is therefore not arbitrary — it is the flavonol half of a pharmaceutical-grade specification. Claim strength: High (specification fact).

The dementia-prevention claim must be addressed honestly, because the evidence is negative and the trial was large. A meta-analysis of two trials involving 5,889 participants found no significant difference in dementia rate between Ginkgo biloba and placebo (347/2,951 versus 330/2,938; odds ratio 1.05), with no considerable heterogeneity between the trials (Charemboon 2015). The GEM study, the largest completed randomized double-blind placebo-controlled dementia-prevention trial to date, used EGb 761 at 120 mg twice daily and found it not effective in reducing incidence of Alzheimer dementia or dementia overall — and a companion analysis found no evidence that it slowed the rate of cognitive decline in older adults either. Formulators must not make dementia-prevention claims for this ingredient. Claim strength: Emerging (negative for prevention).

The picture for existing cognitive impairment is more favourable but genuinely contested and importantly dose-dependent. An overview of systematic reviews of ginkgo extracts for mild cognitive impairment and dementia found improvement in cognition, neuropsychiatric symptoms, and daily activities, with the effect being dose-dependent — and stated that efficacy was convincingly demonstrated only when a high daily dose of 240 mg was applied. This is a crucial and frequently ignored distinction: prevention in healthy people (negative) is a different question from symptomatic treatment of existing impairment at adequate dose (more promising). Claim strength: Emerging.

Ginkgo-specific acylated flavonol glycosides appear to be the pharmacologically distinctive component of the flavonoid fraction, rather than the ordinary flavonols. Research examining EGb 761’s effect on neurotransmitter levels found that two Ginkgo-specific acylated flavonol glycosides increased dopamine and acetylcholine release in the rat medial prefrontal cortex, and specifically noted that this effect appeared not to be a general property of flavonols but a specific action of the acylated glycosides present in the extract. This suggests a "quercetin 24%" equivalent would not reproduce the extract. Claim strength: Emerging (mechanistic).

A critical safety specification unique to this ingredient: ginkgolic acids are cytotoxic and allergenic constituents of ginkgo leaf, and the pharmaceutical specification requires they be held below 5 ppm. This is not a routine purity parameter but a defining safety requirement of a properly manufactured ginkgo extract, and the acetone-based extraction and refinement process used for EGb 761 exists in significant part to achieve it. An extract without a documented ginkgolic acid limit should not be considered pharmaceutical-equivalent regardless of its flavone glycoside assay. Claim strength: High (safety specification).

---

Dosage & Formulator Specification

Herbuno carries Ginkgo biloba leaf extract standardized to the classic 24%/6% specification — 24% flavone glycosides with 6% terpene lactones — alongside unstandardized ginkgo leaf extract powder and water-soluble and oil-soluble formats. The terpene lactone half of this specification is documented separately in this index; buyers should understand that the 24%/6% figures describe two chemically distinct co-specified fractions in a single extract, not two grades.

Clinical dosing has clustered around 120–240 mg/day of standardized extract, and the dose distinction is consequential rather than nominal: the GEM prevention trial used 120 mg twice daily (240 mg/day) and found no preventive benefit, while the systematic-review overview of symptomatic treatment found efficacy convincingly demonstrated only at 240 mg/day. Formulators should size to 240 mg/day where the symptomatic indication is the target, and should not claim preventive benefit at any dose.

Analytical verification must specify three things, not one: flavone glycoside content (target 24%, with pharmacopoeial specifications typically defining a 22–27% range), terpene lactone content (target 6%, typically 5–7%), and — non-negotiably — ginkgolic acid content below 5 ppm. The last is a safety specification rather than a quality nicety. Adulteration of ginkgo extract with cheaper flavonoid sources (notably rutin or buckwheat-derived flavonols) to inflate the flavone glycoside assay is a documented issue in this trade, and a flavonol fingerprint that verifies the expected quercetin:kaempferol ratio is a worthwhile additional check.

Ginkgo extract is generally well tolerated, with mild gastrointestinal effects and headache most commonly reported. Two cautions warrant prominence. Ginkgo has documented antiplatelet activity, and there are case reports of bleeding events, warranting clear caution alongside anticoagulant and antiplatelet medication and before surgery. Separately, ginkgolic acids are the constituents responsible for the allergenic and cytotoxic risk associated with poorly refined ginkgo material, which is precisely why the <5 ppm limit exists and why buyers should insist on documentation of it rather than accepting a flavone glycoside figure alone.

---

Frequently Asked Questions — Ginkgo Flavone Glycosides

Does ginkgo prevent dementia?
No — and this should be stated plainly. A meta-analysis of two trials with 5,889 participants found no significant difference in dementia rates versus placebo. The GEM study, the largest such trial ever run, used 240 mg/day of EGb 761 and found no reduction in Alzheimer or overall dementia incidence, nor any slowing of cognitive decline. Prevention claims are not supportable.

What does the 24%/6% on a ginkgo label mean?
It describes two chemically distinct co-specified fractions in one extract: 24% flavone glycosides (quercetin, kaempferol, and isorhamnetin conjugates) and 6% terpene lactones (ginkgolides and bilobalide, which are unique to ginkgo). It is the EGb 761 pharmaceutical specification, adopted because unstandardized ginkgo varies enormously with season and growing conditions.

What are ginkgolic acids and why do they matter?
They are cytotoxic and allergenic constituents of ginkgo leaf, and the pharmaceutical specification requires they be held below 5 ppm. This is a defining safety requirement, not a routine purity parameter. An extract without a documented ginkgolic acid limit should not be treated as pharmaceutical-equivalent regardless of its flavone glycoside assay.

Is there any cognitive indication ginkgo does support?
Possibly symptomatic treatment of existing cognitive impairment, as distinct from prevention in healthy people. An overview of systematic reviews found improvement in cognition and daily activities in mild cognitive impairment and dementia, but noted efficacy was convincingly demonstrated only at a high daily dose of 240 mg. The evidence remains contested.

Related compounds: Terpene Lactones, Quercetin, Kaempferol, Flavonoids

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery